Showing 1,941 - 1,960 results of 42,148 for search '(( a point decrease ) OR ( 50 ((((we decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.08s Refine Results
  1. 1941

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  2. 1942

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  3. 1943
  4. 1944
  5. 1945
  6. 1946

    Anthelmintics Derived from the Kinase Inhibitor SGI-1776 for the Treatment of Gastrointestinal Worm Infections by Mostafa A. Elfawal (22430138)

    Published 2025
    “…The unexpected SAR of compound <b>15</b> can be explained by computational modeling. We demonstrate the efficacy of optimized compound <b>50</b> as a new oral anthelmintic, which demonstrated better gut restriction properties and significantly reduced the fecundity of T. muris whipworm adults in infected mice. …”
  7. 1947

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
  8. 1948

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
  9. 1949
  10. 1950
  11. 1951

    Recombinant α-SNAP halts the AR at a stage when SNAREs are monomeric. by Facundo Rodríguez (213557)

    Published 2011
    “…<p><i>A</i>, we incubated SLO-permeabilized sperm with 300 nM α-SNAP for 10 min at 37°C followed by 100 nM light chain of TeTx, and 0.5 mM CaCl<sub>2</sub> for an additional 10 min (<i>G</i>, <i>H</i>, <i>I</i>). …”
  12. 1952
  13. 1953
  14. 1954
  15. 1955

    A1, A3 impact force time-history curves. by Khalil AL-Bukhaiti (16015543)

    Published 2023
    “…The axial compression ratio ranged from 0.05 to 0.13 when the impact curve reached its maximum deflection before the component’s impact resistance decreased. Analysis of the impact point and inclined crack location revealed that axial load affects the maximum local concrete. …”
  16. 1956
  17. 1957

    CDK2/Speedy A localization in <i>Cdk2</i><sup><i>−/−</i></sup> and <i>Speedy A</i><sup><i>−/−</i></sup> spermatocytes. by Nathan Palmer (264897)

    Published 2020
    “…Highlighted by dashed lines are intervals in which telomeres were found to have a 50%–74% decrease in signal and a 75%–100% decrease in signal. …”
  18. 1958
  19. 1959
  20. 1960